CN Patent

CN104922084A — 布洛芬钠片剂和制备包含布洛芬钠的药物组合物的方法

Assigned to PF Consumer Healthcare 1 LLC · Expires 2015-09-23 · 11y expired

What this patent protects

描述了布洛芬钠组合物以及制备包含布洛芬钠的片剂和胶囊形片剂的方法。该制剂是有利的，因为它允许形成具有较低钠量的片剂，此外还提供显示改善的物理稳定性、较高的片硬度和高强度，并配合优良的溶解和生物利用度性质的片剂。该制剂和方法还更近一步地有利，因为它们可以大批量地生产而没有不可接受数量的有缺陷片剂。

USPTO Abstract

描述了布洛芬钠组合物以及制备包含布洛芬钠的片剂和胶囊形片剂的方法。该制剂是有利的，因为它允许形成具有较低钠量的片剂，此外还提供显示改善的物理稳定性、较高的片硬度和高强度，并配合优良的溶解和生物利用度性质的片剂。该制剂和方法还更近一步地有利，因为它们可以大批量地生产而没有不可接受数量的有缺陷片剂。

Drugs covered by this patent

fingolimod-lauryl-sulfate (FINGOLIMOD LAURYL SULFATE)

Patent Metadata

Patent number: CN104922084A
Jurisdiction: CN
Classification: —
Expires: 2015-09-23
Drug substance claim: No
Drug product claim: No
Assignee: PF Consumer Healthcare 1 LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.